参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Colon Cancer Version 1.2019— March 15,2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed.,2017).
3.Cooper HS,Deppisch LM,Gourley WK,et al.Endoscopically removed malignant colorectal polyps: clinicopathologic correlations.Gastroenterology 1995, 108: 1657-1665.
4.Higurashi T,Hosono K,Takahashi H,et al.Metformin for chemoprevention of metachronous colorectal adenoma or polyps inpostpolypectomy patients without diabetes: a multicentre double-blind,placebo-controlled,randomised phase 3 trial.Lancet Oncol 2016, 17: 475-483.
5.GillS,Haince JF,Shi Q,et al.Prognostic value of molecular detection of lymph node metastases after curative resection of stage II colon cancer: a systematic pooled data analysis.Clin Colorectal Cancer 2015, 14: 99-105.
6.Sabbagh C,Mauvais F,Cosse C,et al.A lymph node ratio of 10% is predictive of survival in stage III colon cancer: a French regional study.Int Surg 2014, 99: 344-353.
7.Zarak A,Castillo A,Kichler K,et al.Robotic versus laparoscopic surgery for colonic disease: a meta-analysis of postoperative variables.Surg Endosc 2015, 29: 1341-1347.
8.Casadaban L,Rauscher G,Aklilu M,et al.Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.Cancer 2016, 122: 3277-3287.
9.Pahlman LA,Hohenberger WM,Matzel K,et al.Should the benefit of adjuvant chemotherapy in colon cancer be reevaluated? J Clin Oncol 2016, 34: 1297-1299.
10.Kim JE,Hong YS,Kim HJ,et al.Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy.Ann Surg Oncol 2015, 22 Suppl 3: S630-637.
11.Schmoll HJ,Tabernero J,Maroun J,et al.Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial.J Clin Oncol 2015, 33: 3733-3740.(https://www.daowen.com)
12.Kerr RS,Love S,Segelov E,et al.Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer(QUASAR 2): an openlabel,randomised phase 3 trial.Lancet Oncol 2016, 17: 1543-1557.
13.Taieb J,Balogoun R,Le Malicot K,et al.Adjuvant FOLFOX+/-cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.Ann Oncol 2017, 28: 824-830.
14.Zacharias AJ,Jayakrishnan TT,Rajeev R,et al.Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis.PLoS One 2015, 10: e0139940.
15.Martin RC,2nd,Scoggins CR,Schreeder M,et al.Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.Cancer 2015, 121: 3649-3658.
16.Chan DL,Alzahrani NA,Morris DL,et al.Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases.Surg Oncol 2015, 24: 162-171.
17.Wang ZM,Chen YY,Chen FF,et al.Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis.Eur J Surg Oncol 2015, 41: 1197-1203.
18.Brandi G,De Lorenzo S,Nannini M,et al.Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and metaanalysis.World J Gastroenterol 2016, 22: 519-533.
19.Deenen MJ,Meulendijks D,Cats A,et al.Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis.J Clin Oncol 2016, 34: 227-234.
20.Aparicio T,Lavau-Denes S,Phelip JM,et al.Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer(FFCD 2001-02).Ann Oncol 2016, 27: 121-127.
21.Snoeren N,van Hillegersberg R,Schouten SB,et al.Randomized phase III study to assess efficacy and safety of adjuvant CAPOX with or without bevacizumab in patients after resection of colorectal liver metastases: HEPATICA study.Neoplasia 2017, 19: 93-99.
22.Warschkow R,Sulz MC,Marti L,et al.Better survival in right-sided versus left-sided stage I～III colon cancer patients.BMC Cancer 2016, 16: 554.